NCT00880490View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Inhaled PT005

single dose, inhaled

DRUG

Inhaled PT005

single dose, inhaled

DRUG

Inhaled PT005

single dose, inhaled

DRUG

Inhaled placebo

single dose, inhaled

DRUG

Formoterol Fumarate 12 mcg (Foradil Aerolizer)

single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer

Trial Locations (5)

2037

Woolcock Institute of Medical Research, Glebe

4066

Australian Clinical Research Organisation, Auchenflower

4101

Mater Hospital, South Brisbane

6035

P3 Research, Wellington

8014

Primorus Clinical Trials, Christchurch

Sponsors
All Listed Sponsors
lead

Pearl Therapeutics, Inc.

INDUSTRY